
Congrats to our @MonteHeart clinician-scientists who ranked #1 in the @crfheart Scientific Excellence Top Ten for their significant contributions to interventional cardiovascular research in the Structural Category! #MonteProud #TCT2026 @EinsteinMed

Official account #MonteInterventionalCardiology #MontePreventiveCardiology #MonteStructuralHeart #MonteEP #MonteHeartFailure #MonteImaging. Tweets≠endorsements.

Congrats to our @MonteHeart clinician-scientists who ranked #1 in the @crfheart Scientific Excellence Top Ten for their significant contributions to interventional cardiovascular research in the Structural Category! #MonteProud #TCT2026 @EinsteinMed

MonteHeart Lectures: Mauro Gitto (Humanitas, Milan) on bailout stenting in a DCB-based PCI strategy. Tuesday 29 Sep, 7:30am ET. einsteinmed.zoom.us/j/942854… @MonteHeart @MontefioreNYC @EinsteinMed @AndreaScotti21 @leoneppmd @lvjulien_md @andrea_mignatti @m_assafin

⚠️ 1 in 5 patients undergoing M-TEER for primary MR has severe TR at baseline Their 2-year mortality: 29.6% (TR ≥Sev) vs 19.6% (TR ≤Mod) @CircIntv 🔗doi.org/10.1161/CIRCINTERVEN… 🧵 (1/4)

Beyond stenosis: imaging phenotyping and risk stratification in nonobstructive coronary artery disease shorturl.at/fI2bu @pamelapina_s @AnnalisaFiltz @danilorenzatti @Ankurdee1 @JaideepBha35378 @Piotr_JSlomka @danielbermanmd @damini_dey @MonteHeart @MontefioreNYC @EinsteinMed

South Asian Cardiovascular Risk: Role of Coronary Artery Calcium Scoring and Computed Tomography Angiography. Outstanding work led by @DineshKalra and @virani_md just published in @JACCJournals jacc.org/doi/10.1016/j.jacas… @MontefioreNYC @MonteHeart @EinsteinMed

Dear Faculty, Fellows, Residents and Friends We invite you to join our @MonteHeart Grand Rounds Tuesday Aug 4, 2026 with @CardioMDPhD From 7:30 am EST – 8:30 am EST Link to join: einsteinmed.zoom.us/j/915580…

Happy to share our editorial, "Another Win for Lifestyle Medicine: Cardiac Rehabilitation–Based Therapy for ANOCA," published in JACC: Cardiovascular Interventions alongside the important SAMCRO randomized trial. Despite the absence of obstructive coronary artery disease, patients with angina and no obstructive coronary arteries (ANOCA) often experience persistent symptoms, impaired quality of life, repeated testing, and uncertainty regarding their diagnosis. The challenge is no longer simply recognizing ANOCA but delivering effective, comprehensive treatment. Congratulations to the investigators for advancing the field with high-quality randomized evidence, and to my co-authors Chip Lavie and Fabian Sanchis-Gomar for the opportunity to collaborate on this editorial. Editorial: authors.elsevier.com/a/1nVvY… Original research: sciencedirect.com/science/ar… @CarlLavie31733 @MonteHeart @JACCJournals @ElsevierConnect

Proud to share our review, now published in @ESC_Journals! PAD is an overlooked form of systemic atherosclerosis with a devastating prognosis. Time to bring it to the forefront of CV prevention. 🔗 academic.oup.com/eurheartj/a… @CardioMDPhD @DLBHATTMD @DrMichaelShapir @MarcBonaca

In MESA, we evaluated cardiovascular event rates across CAC strata within 10-year PREVENT-ASCVD risk categories and statin eligibility groups defined by the 2026 ACC/AHA Multisociety Dyslipidemia Guideline. @JACCJournals @DrMichaelShapir jacc.org/doi/10.1016/j.jacc.…

Congrats to our @MonteHeart @CardioMDPhD Dr. Leandro Slipczuk, current Editor in Chief of @PCVDJournal which is now ranked #15 among cardiovascular medicine journals worldwide. We are #MonteProud! @EinsteinMed

New TAVR, live at #NYValves2026 Live Case Session 10 (Mirus & DurAVR®) Thu June 25 | 9:10–10:10 AM Live Case Theater 🔹 Siegel TAVR (Mirus): Piedmont, Atlanta 🔹 DurAVR® (Anteris): Montefiore, NY Two live cases. Two new platforms. See you there! 🔗 nyvalvesconference.com/progr… x.com/AndreaScotti21/status/…

Proud to share that @PCVDJournal has achieved an Impact Factor of 10.6, ranking #15 among 237 cardiovascular journals worldwide. This remarkable milestone reflects the dedication of our authors, reviewers, editorial board members, and readers who continue to advance the field through high-quality scholarship and scientific rigor. We are especially grateful for the extraordinary leadership of the former EIC @CarlLavie31733, whose vision, commitment to excellence, and many years of service helped build the journal into the highly respected publication it is today. This achievement stands on the strong foundation he created. As we celebrate this accomplishment, we remain committed to publishing impactful reviews, top-quality original research and advancing knowledge that improves cardiovascular health worldwide. Thank you to everyone who has contributed to this success. The future of PCVD is bright. sciencedirect.com/journal/pr…

Sharing our review of the top 10 takeaways for primary prevention from the 2026 Multisociety Dyslipidemia Guideline. Thank you to the great co-authors, including @AbdulMannan5465 and @virani_md pubmed.ncbi.nlm.nih.gov/4229…

In a multicenter PET registry, patients with no evidence of flow-limiting CAD and discordantly low subendocardial myocardial flow reserve (MFR) had an increased risk of MACE than those with normal transmural & subendocardial MFR. ahajrnls.org/444SnyD

🚨 HIV+ Donors for HIV+ Recipients: Win–Win? Want to learn more from the team that has performed the most HIV +/+ 🫀 transplants in the world? Join us at #MonteHeart on June 11 & 12! Registration➡️ eeds.com/live/867139 For info and full agenda ⤵️ @MonteHeart @azeemlatib

🔥 ATTR Amyloid First-line therapy: 🟢 Stabilizer? 🔵 Silencer? Watch Dr. @yogitar and Dr. Tauras in a fast-paced debate at #MonteHeart2026 eeds.com/live/867139 #CardioTwitter #Amyloidosis